PDF下载 ( 2015 KB)
Downstaging and conversion treatment of intermediate and advanced liver cancer should be taken seriously
-
摘要:
外科手术治疗是肝癌获得根治和长期生存的最有效途径。目前,大部分中晚期肝癌患者不能获得根治性手术治疗。临床实践中需高度关注并深入探讨中晚期肝癌的降期转化治疗策略,进一步提高疗效。根据中晚期肝癌患者的不同分期和具体病情,多学科团队协作,优化降期转化治疗方案,有望使不能手术切除的患者获得手术治疗,姑息性治疗转化为根治性手术切除,不能抗肿瘤治疗的患者可接受姑息性治疗,更多的中晚期肝癌患者疗效提高,预后改善,长期生存。
Abstract:Surgical treatment is the most effective approach to achieving radical treatment and long-term survival of liver cancer. At present,most patients with intermediate and advanced liver cancer do not have the opportunity to receive radical surgery. The downstaging and conversion treatment strategies for intermediate and advanced liver cancer should be taken seriously in clinical practice to further improve treatment outcome. According to disease stage and conditions of patients with intermediate and advanced liver failure,multidisciplinary cooperation is needed to optimize downstaging and conversion treatment regimens,which may help inoperable patients to obtain the opportunity for surgical treatment. Palliative therapy can be changed to radical surgical resection,and patients who cannot undergo antitumor treatment can still receive palliative therapy. More patients with intermediate and advanced liver cancer are able to achieve a better clinical outcome,an improvement in prognosis,and long-term survival.
-
[1] ZHENG RS,SUN KX,ZHANG SW,et al. Report of cancer epidemiology in China,2015[J]. Chin J Oncol,2019,41(1):19-28.(in Chinese)郑荣寿，孙可欣，张思维，等．2015年中国恶性肿瘤流行情况分析[J]．中华肿瘤杂志，2019,41(1):19-28. [2] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314. [3] LLOVET JM,MONTAL R,SIA D,et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol,2018,15(10):599-616. [4] VILLANUEVA A. Hepatocellular carcinoma[J]. New Engl J Med,2019,380(15):1450-1462. [5] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431. [6] Bureau of Medical Administration,National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局．原发性肝癌诊疗规范(2019年版)[J]．临床肝胆病杂志，2020,36(2):277-292. [7] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236. [8] MARRERO JA,KULIK LM,SIRLIN CB,et al. Diagnosis,staging, and management of hepatocellular carcinoma:2018practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2018,68(2):723-750. [9] VOGEL A,CERVANTES A,CHAU I,et al. Hepatocellular carcinoma:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2018,29(Suppl 4):iv238-iv255. [10] WEI X,JIANG Y,ZHANG X,et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus:A randomized,open-label,multicenter controlled study[J]. J Clin Oncol,2019,37(24):2141-2151. -
本文二维码
计量
- 文章访问数: 1406
- HTML全文浏览量: 68
- PDF下载量: 386
- 被引次数: 0
下载:
